Markets:

Overview

News

Currencies

International

Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

7.686 +0.006 (+0.08%)

Streaming Delayed Price Updated: 3:06 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Latest Analyst Ratings for 4D Molecular Therapeutics ↗

April 13, 2023

Via Benzinga

SVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Know ↗

April 13, 2023

Via Benzinga

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

April 13, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

7 Biotech Stocks Sitting in the Sweet Spot ↗

March 24, 2023

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.

Via InvestorPlace

Expert Ratings for 4D Molecular Therapeutics ↗

March 16, 2023

Via Benzinga

Analyst Ratings for 4D Molecular Therapeutics ↗

January 30, 2023

Via Benzinga

Expert Ratings for 4D Molecular Therapeutics ↗

November 18, 2022

Via Benzinga

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

March 15, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study ↗

February 23, 2023

Via Benzinga

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

February 22, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™

February 16, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

February 08, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

February 02, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target' ↗

January 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

January 09, 2023

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

How Is The Market Feeling About 4D Molecular Therapeutics? ↗

December 15, 2022

4D Molecular Therapeutics's (NASDAQ:FDMT) short percent of float has fallen 15.19% since its last report. The company recently reported that it has 2.29 million shares sold short, which is 8.82% of all...

Via Benzinga

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday ↗

November 23, 2022

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

November 21, 2022

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street ↗

November 20, 2022

Recent analyst upgrades suggest these stocks can triple your money or better.

Via The Motley Fool

HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential' ↗

November 18, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗

November 18, 2022

Upgrades

Via Benzinga

Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher' ↗

November 18, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."

Via Benzinga

Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday ↗

November 17, 2022

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.

Via Benzinga

Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday ↗

November 16, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.

Via Benzinga

Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday ↗

November 16, 2022

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session ↗

November 15, 2022

Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.

Via Benzinga

Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected ↗

November 15, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 15, 2022

Gainers Azenta (NASDAQ:AZTA) shares rose 32.5% to $61.74 during Tuesday's pre-market session. The company's market cap stands at $4.6 billion. As per the news, the Q4 earnings report came out...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.